Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Dana-Farber Cancer Institute, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Boston, MA
Treatments:Biologic therapyHospital:Dana-Farber Cancer Institute
Drugs:Journal:Link
Date:Jun 2012

Description:

Patients:
This phase 2 study involved 41 female, HER2-positive metastatic breast cancer patients who had been previously treated with trastuzumab. The median patient age was 54 years.

Treatment:
Patients were treated with biologic therapy agent afatinib, which is a tyrosine kinase inhibitor that inhibits the HER2 and EGFR proteins.

Toxicities:
The most severe toxicities were of grade 3 and included diarrhea, rash, and vomiting.

Results:
The median overall survival was 14 months.

Support:
This study was supported by Boehringer Ingelheim, makers of afatinib.

Correspondence: Dr. Nancy Lin; email: [email protected]



Back